Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paracetamol + ketamine is a combination medication used for pain management in various clinical settings. This combination leverages the complementary mechanisms of action of both drugs to provide enhanced analgesia with potentially fewer side effects than higher doses of either drug alone. **Mechanism of Action:** - **Paracetamol** works primarily by inhibiting prostaglandin synthesis and has both analgesic and antipyretic properties. It's also believed to be related to the serotonin system and may interfere with nociception related to spinal NMDA receptor activation. - **Ketamine** is a non-competitive NMDA receptor antagonist that acts post-synaptically to reduce the hyperexcitability of spinal nociceptors. It also has antinociceptive effects by inhibiting sodium and voltage-dependent calcium channels. The combination has demonstrated synergistic analgesic effects, particularly when ketamine is used at low doses (0.5-1 mg/kg). This allows for effective pain management while minimizing the side effects associated with higher doses of ketamine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + ketamine.